Gradual dose escalation helps to minimize common gastrointestinal side effects
Targets NNMT to enhance fat metabolism and reduce fat cell growth
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
The primary endpoint is the time to the first occurrence of a composite primary outcome event, defined as a persistent eGFR decline (50% from baseline), reaching ESRD, renal death, or CV death
Triglycerides dropped by 31 percent
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 receptor and related metabolic pathwaysincluding GIPR rs1800437, FTO rs9939609, and MC4R rs17782313to help identify genetic predispositions that may influence how your body responds to semaglutide dosing and escalation